Cargando…
Efficacy and Safety of Shuganjieyu Capsule Alone or in Combination with Other Antidepressants in the Treatment of Postpartum Depression: A Meta-Analysis
OBJECTIVE: To evaluate the efficacy and safety of Shuganjieyu capsule alone or in combination with other antidepressants in the treatment of postpartum depression. METHODS: Related control and randomized studies till August 1, 2021, were retrieved from the following databases: PubMed, Cochrane, CNKI...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283059/ https://www.ncbi.nlm.nih.gov/pubmed/35845579 http://dx.doi.org/10.1155/2022/5260235 |
_version_ | 1784747251926564864 |
---|---|
author | Wang, Lingning Fan, Yan He, Jiangmen Liu, Heng Chen, Feng Dan, Hongying Zhao, Juan Zhang, Jiao Wang, Tao Liu, Xinru |
author_facet | Wang, Lingning Fan, Yan He, Jiangmen Liu, Heng Chen, Feng Dan, Hongying Zhao, Juan Zhang, Jiao Wang, Tao Liu, Xinru |
author_sort | Wang, Lingning |
collection | PubMed |
description | OBJECTIVE: To evaluate the efficacy and safety of Shuganjieyu capsule alone or in combination with other antidepressants in the treatment of postpartum depression. METHODS: Related control and randomized studies till August 1, 2021, were retrieved from the following databases: PubMed, Cochrane, CNKI, CMB, Wan-Fang, and VIP. Outcomes included HAMD reduction from baseline, response rate, and adverse events rate. Review Manager 5.3 was used in the present meta-analysis. RESULTS: 16 studies including 1409 participants were included in the present study. In comparison of single Shuganjieyu capsule versus regular antidepressant, 8, 6, and 4-week HAMD reduction of the Shuganjieyu group were significantly higher (8-week MD: 3.1 (1.54, 4.66), p < 0.0001; 6-week MD: 0.71 (0.10, 1.31), p=0.02; and 4-week MD: 0.82 (0.34, 1.30), p=0.0008), response rates were comparable for the two groups (OR: 1.51 (0.87, 2.63), p=0.014), and the adverse event rate of the Shuganjieyu group was significantly lower (OR: 0.22 (0.15, 0.32), p < 0.00001). In comparison of combination of Shuganjieyu capsule with regular antidepressant versus regular antidepressant alone, the 8, 6, 4, 2, and 1-week HAMD reduction and response rate of combination of Shuganjieyu with the regular antidepressant group were significantly larger (8-week MD: 3.2 (1.34, 5.06), p=0.0007; 6-week MD: 4.00 (2.72, 5.28), p < 0.00001; 4-week MD: 3.33 (1.94,4.73), p < 0.00001; 2-week MD: 2.69 (1.34, 4.03), p < 0.0001; 1-week MD: 2.27 (0.69, 3.86), p=0.005; and response rate OR: 4.69 (2.27, 9.68), p < 0.0001) and the adverse event rate was comparable for the two groups (OR: 1.26 (0.73, 2.17), p=0.41). CONCLUSION: Compared with regular antidepressants, single Shuganjieyu capsule has similar efficacy and better safety profile; when Shuganjieyu capsule is combined with regular antidepressants, the efficacy is improved significantly without increasing adverse events. Therefore, Shuganjieyu capsule was effective and safe for postpartum, making it worth further investigation and popularization. |
format | Online Article Text |
id | pubmed-9283059 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Hindawi |
record_format | MEDLINE/PubMed |
spelling | pubmed-92830592022-07-15 Efficacy and Safety of Shuganjieyu Capsule Alone or in Combination with Other Antidepressants in the Treatment of Postpartum Depression: A Meta-Analysis Wang, Lingning Fan, Yan He, Jiangmen Liu, Heng Chen, Feng Dan, Hongying Zhao, Juan Zhang, Jiao Wang, Tao Liu, Xinru Evid Based Complement Alternat Med Review Article OBJECTIVE: To evaluate the efficacy and safety of Shuganjieyu capsule alone or in combination with other antidepressants in the treatment of postpartum depression. METHODS: Related control and randomized studies till August 1, 2021, were retrieved from the following databases: PubMed, Cochrane, CNKI, CMB, Wan-Fang, and VIP. Outcomes included HAMD reduction from baseline, response rate, and adverse events rate. Review Manager 5.3 was used in the present meta-analysis. RESULTS: 16 studies including 1409 participants were included in the present study. In comparison of single Shuganjieyu capsule versus regular antidepressant, 8, 6, and 4-week HAMD reduction of the Shuganjieyu group were significantly higher (8-week MD: 3.1 (1.54, 4.66), p < 0.0001; 6-week MD: 0.71 (0.10, 1.31), p=0.02; and 4-week MD: 0.82 (0.34, 1.30), p=0.0008), response rates were comparable for the two groups (OR: 1.51 (0.87, 2.63), p=0.014), and the adverse event rate of the Shuganjieyu group was significantly lower (OR: 0.22 (0.15, 0.32), p < 0.00001). In comparison of combination of Shuganjieyu capsule with regular antidepressant versus regular antidepressant alone, the 8, 6, 4, 2, and 1-week HAMD reduction and response rate of combination of Shuganjieyu with the regular antidepressant group were significantly larger (8-week MD: 3.2 (1.34, 5.06), p=0.0007; 6-week MD: 4.00 (2.72, 5.28), p < 0.00001; 4-week MD: 3.33 (1.94,4.73), p < 0.00001; 2-week MD: 2.69 (1.34, 4.03), p < 0.0001; 1-week MD: 2.27 (0.69, 3.86), p=0.005; and response rate OR: 4.69 (2.27, 9.68), p < 0.0001) and the adverse event rate was comparable for the two groups (OR: 1.26 (0.73, 2.17), p=0.41). CONCLUSION: Compared with regular antidepressants, single Shuganjieyu capsule has similar efficacy and better safety profile; when Shuganjieyu capsule is combined with regular antidepressants, the efficacy is improved significantly without increasing adverse events. Therefore, Shuganjieyu capsule was effective and safe for postpartum, making it worth further investigation and popularization. Hindawi 2022-07-07 /pmc/articles/PMC9283059/ /pubmed/35845579 http://dx.doi.org/10.1155/2022/5260235 Text en Copyright © 2022 Lingning Wang et al. https://creativecommons.org/licenses/by/4.0/This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Review Article Wang, Lingning Fan, Yan He, Jiangmen Liu, Heng Chen, Feng Dan, Hongying Zhao, Juan Zhang, Jiao Wang, Tao Liu, Xinru Efficacy and Safety of Shuganjieyu Capsule Alone or in Combination with Other Antidepressants in the Treatment of Postpartum Depression: A Meta-Analysis |
title | Efficacy and Safety of Shuganjieyu Capsule Alone or in Combination with Other Antidepressants in the Treatment of Postpartum Depression: A Meta-Analysis |
title_full | Efficacy and Safety of Shuganjieyu Capsule Alone or in Combination with Other Antidepressants in the Treatment of Postpartum Depression: A Meta-Analysis |
title_fullStr | Efficacy and Safety of Shuganjieyu Capsule Alone or in Combination with Other Antidepressants in the Treatment of Postpartum Depression: A Meta-Analysis |
title_full_unstemmed | Efficacy and Safety of Shuganjieyu Capsule Alone or in Combination with Other Antidepressants in the Treatment of Postpartum Depression: A Meta-Analysis |
title_short | Efficacy and Safety of Shuganjieyu Capsule Alone or in Combination with Other Antidepressants in the Treatment of Postpartum Depression: A Meta-Analysis |
title_sort | efficacy and safety of shuganjieyu capsule alone or in combination with other antidepressants in the treatment of postpartum depression: a meta-analysis |
topic | Review Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9283059/ https://www.ncbi.nlm.nih.gov/pubmed/35845579 http://dx.doi.org/10.1155/2022/5260235 |
work_keys_str_mv | AT wanglingning efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis AT fanyan efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis AT hejiangmen efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis AT liuheng efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis AT chenfeng efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis AT danhongying efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis AT zhaojuan efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis AT zhangjiao efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis AT wangtao efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis AT liuxinru efficacyandsafetyofshuganjieyucapsulealoneorincombinationwithotherantidepressantsinthetreatmentofpostpartumdepressionametaanalysis |